No Picture
News

At two-year follow-up, Evrysdi continues to show numerical improvements in data, Roche says

A little less than two months after receiving an FDA approval in spinal muscular atrophy, Roche’s Genentech continues to roll out data for risdiplam.
The drug, marketed as Evrysdi in the US, showed improved motor functions in infants as part of a two-y… […]

No Picture
News

Gilead wins a blockbuster consolation prize with EC, Japanese approvals for filgotinib — but that barely softens the blow of the FDA’s CRL

The FDA’s recent slapdown of Gilead’s rheumatoid arthritis JAK filgotinib didn’t even slightly delay its arrival in 2 big world markets. The EC stamped its marketing authorization on the blockbuster candidate at the end of the week, following the news … […]

No Picture
News

Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with symptom… […]

No Picture
News

Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammatio… […]

No Picture
News

Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) — Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the addition of David J. Woodhouse, Ph.D., to the Board of Directors. D… […]